Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by arteriopathy in the small to medium-sized distal pulmonary arteries, often accompanied by infiltration of inflammatory ...

Although some cases of PAH have known causes, such as genetic factors, many cases have no identifiable underlying cause and are designated as idiopathic. Early diagnosis and treatment are critical for ...

Though circulating high mobility group box-1 levels appear to be a biomarker for pulmonary arterial hypertension (PAH) in adults with congenital heart disease, the same is not true in pediatric ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

MANCHESTER, England — Use of immunosuppressive drugs within 5 years of the onset of systemic sclerosis (SSc) did not lower patients’ risk for developing pulmonary arterial hypertension (PAH) but was ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Expert Rev Cardiovasc Ther. 2012;10(11):1367-1373. The elderly merit special consideration for BP measurement. These hypertensive patients are prone to have autonomic failure with postural hypotension ...

Pulmonary arterial hypertension, a disease that leads to worsening lung and heart problems that eventually become life-threatening, is treated with drugs that alleviate symptoms. FDA approval of a new ...